Innogenetics NV develops and markets diagnostic products for therapy management and patient health. Its diagnostics business focuses on developing products for infectious diseases, genetic testing, tissue typing, neurodegeneration, and oncology. Its products in the area of infectious diseases include screening and confirmation tests for HIV, HCV, HTLV, and syphilis; genotyping tests for hepatitis B virus (HBV), human papillomavirus, and mycobacterium sp; and drug-resistance tests for TB and HBV. Innogenetics also offers genetic testing products comprising detection tests for cystic fibrosis, as well as MBL2 and APO E genetic variants associated with genetic risks; tissue typing tests to determine the type of HLA; and neurodegeneration products, which include tests for Alzheimer's disease. In the Oncology area, the company distributes AdnaGen AGÃ¢â‚¬â„¢s diagnostics products for breast and colon cancer. Its therapeutics business engages in the development of therapeutic vaccines for the treatment of infectious diseases caused by hepatitis C, hepatitis B, and human papillomaviruses. The companyÃ¢â‚¬â„¢s therapeutic portfolio includes GNI-102, a polyepitope vaccine candidate, which is in phase I clinical trial targeting HBV; GNI-104, which are anti-HCV neutralizing human monoclonal antibodies; and GNI-105, a HPV polyepitope vaccine candidate. It has collaborative research, development, distribution, or licensing agreements with Solvay Pharmaceuticals BV; sanofi-aventis; Takeda Chemical Industries; Immuno-Biological Laboratories Co; Roche Group of companies; AdnaGen AG; Siemens Healthcare Diagnostics; Danisco A/S; Pharmexa-Epimmune, Inc.; and PamGene International BV. It sells its products primarily in Germany, Italy, France, Spain, the United States, Brazil, Switzerland, Austria, the Benelux, and Eastern Europe. It was founded in 1985 and is based in Gent, Belgium. As of November 20, 2008, Innogenetics NV operates as a subsidiary of Solvay Pharmaceuticals S.A.